Synthetic Biologics, Inc. Form 4 January 12, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box subject to

if no longer Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

Synthetic Biologics, Inc. [SYN]

(Print or Type Responses)

(Last)

412

1. Name and Address of Reporting Person * Riley Jeffrey Scott

(First)

C/O SYNTHETIC BIOLOGICS.

(Middle)

(Month/Day/Year) 01/08/2015 INC.,, 155 GIBBS STREET, SUITE

Symbol

(Street)

ROCKVILLE, MD 20850

4. If Amendment, Date Original

3. Date of Earliest Transaction

Filed(Month/Day/Year)

_X__ Director

X_ Officer (give title Other (specify below) CEO and President

6. Ownership

Form: Direct

(Instr. 4)

(Check all applicable)

10% Owner

7. Nature of

Ownership

(Instr. 4)

Indirect

(D) or Indirect Beneficial

5. Relationship of Reporting Person(s) to

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

(City) 1. Title of

Security

(Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(State)

(Zip)

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8)

(Instr. 3, 4 and 5) (A)

or

Beneficially Owned Following Reported

5. Amount of

Securities

Transaction(s) (Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion 3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if

5. Number of TransactionDerivative

6. Date Exercisable and **Expiration Date**

7. Title and Amount Underlying Securities

Edgar Filing: Synthetic Biologics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		r)	(Instr. 3 and 4	4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amous Number Shares
Stock Options	\$ 1.54	01/08/2015		A	350,000 (1)	01/08/2015(1)	01/08/2025	Common Stock	350,0

Reporting Owners

Reporting Owner Name / Address	Relationships					
coporting of the rando, randous	Director	10% Owner	Officer	Other		
Riley Jeffrey Scott C/O SYNTHETIC BIOLOGICS, INC., 155 GIBBS STREET, SUITE 412 ROCKVILLE, MD 20850	X		CEO and President			

Signatures

/s/ Jeffrey S.
Riley

**Signature of Reporting Person

O1/12/2015

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options will vest quarterly on a pro rated basis over 36 consecutive months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2